Search
Vertex Pharmaceuticals Inc
VRTXAdd to Watchlist
468.805USD
+2.015+0.43%
Market hours （ET）Quotes delayed by 15 min
119.15BMarket Cap
27.57P/E TTM
More Details of Vertex Pharmaceuticals Inc Company
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Vertex Pharmaceuticals Inc Info
Ticker SymbolVRTX
Company nameVertex Pharmaceuticals Inc
IPO dateJul 24, 1991
CEOKewalramani (Reshma)
Number of employees6100
Security typeOrdinary Share
Fiscal year-endJul 24
Address50 Northern Avenue
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02210
Phone16173416393
Websitehttps://www.vrtx.com/
Ticker SymbolVRTX
IPO dateJul 24, 1991
CEOKewalramani (Reshma)
Company Executives of Vertex Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
47.80K
+28.61%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
45.00K
--
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
35.24K
--
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
29.50K
+12.65%
Ms. Joy Liu
Ms. Joy Liu
Corporate Secretary
Corporate Secretary
19.90K
-4.16%
Mr. Jonathan Biller, J.D.
Mr. Jonathan Biller, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
13.66K
-78.45%
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Independent Director
Independent Director
4.92K
+12.69%
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
1.62K
-359.34%
Ms. Jennifer J. Schneider
Ms. Jennifer J. Schneider
Independent Director
Independent Director
1.39K
-23.24%
Mr. Michel Lagarde
Mr. Michel Lagarde
Independent Director
Independent Director
1.13K
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
47.80K
+28.61%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
45.00K
--
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
35.24K
--
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
29.50K
+12.65%
Ms. Joy Liu
Ms. Joy Liu
Corporate Secretary
Corporate Secretary
19.90K
-4.16%
Mr. Jonathan Biller, J.D.
Mr. Jonathan Biller, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
13.66K
-78.45%
FAQs
Who are the top five shareholders of Vertex Pharmaceuticals Inc?
The top five shareholders of Vertex Pharmaceuticals Inc are: Dr. Reshma Kewalramani
How many institutions hold shares of Vertex Pharmaceuticals Inc (VRTX)?
As of 2026Q1, 3075 institutions hold shares of Vertex Pharmaceuticals Inc, with a combined market value of approximately 247.47M, accounting for 97.50% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -4593876.00.
What is the biggest source of revenue for Vertex Pharmaceuticals Inc?
In 2026Q1, the TRIKAFTA business generated the highest revenue for Vertex Pharmaceuticals Inc, amounting to 10.31B and accounting for 86.15% of total revenue.
